By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
US FDA investigates Takeda's blood disorder drug after pediatric death - 2Three arrested in Paris after attempted bomb attack outside Bank of America
- 3NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says
- 4How Mars' ancient lakes grew shields of ice to stay warm as the Red Planet froze
- 5See a half-lit moon shine among the stars of Aquarius on Nov. 27
- 'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Zendaya's 'Breaking Bad' era
- Porsche May Kill the Electric Boxster Before It Ever Arrives
- The pinch at the pump continues on
- Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- Benedict Cumberbatch takes on something even Sherlock can’t solve: male grief
- White House responds to Sabrina Carpenter after pop star slams 'evil' ICE video using her song
- Iran war drives global fertilizer prices up, raising food cost fears
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Israel approves 19 new West Bank settlements in major annexation push
